Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: zika virus vaccine - GlaxoSmithKline/NIH

Drug Profile

Research programme: zika virus vaccine - GlaxoSmithKline/NIH

Latest Information Update: 28 Aug 2020

At a glance

  • Originator GlaxoSmithKline; National Institutes of Health (USA)
  • Class RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Zika virus infection

Most Recent Events

  • 28 Aug 2020 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA
  • 07 Jul 2016 Early research in Zika virus infection (Prevention) in USA (unspecified route)

Development Overview

Introduction

GlaxoSmithKline and National Institutes of Health (NIH) are collaborating to develop a vaccine to prevent spread of Zika virus infections. The company intends to utilise its novel self-amplifying mRNA (SAM) technology for the vaccine. Early research is currently underway in the US.

As at August 2020, no recent reports of development had been identified for research development in Zika-virus-infection (Prevention) in USA.

Key Development Milestones

In July 2016, GSK announced that the feasibility assessment studies for designing zika virus vaccine had completed and that the company is planning to initiate laboratory-based studies, in collaboration with various facilities at the NIH [1] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class RNA vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Zika virus infection - Prevention No development reported (Research) USA unspecified / unspecified GlaxoSmithKline, National Institutes of Health (USA) 28 Aug 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
GlaxoSmithKline Originator United-Kingdom
National Institutes of Health (USA) Originator USA
National Institutes of Health (USA) Owner USA
GlaxoSmithKline Owner United-Kingdom

Development History

Event Date Update Type Comment
28 Aug 2020 Phase Change - No development reported No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA Updated 28 Aug 2020
07 Jul 2016 Phase Change Early research in Zika virus infection (Prevention) in USA (unspecified route) Updated 27 Jul 2016

References

  1. Update on GSK's response to the Zika virus disease outbreak.

    Media Release
Back to top